New Drug Approvals in Oncology

This viewpoint presents a debate about the evolving regulatory paradigm for cancer drugs, with the authors arguing that newer expedited approval pathways have accelerated access to beneficial therapies and that delays in drug approval have historically cost tens of thousands of patient life-years, while acknowledging the need for rigorous evidence standards.